Ruby Kelvin
63 posts
















I’ve said this before: I believe consumer biotech will become the most compelling sub-sector within biotech - without question - and one of the most attractive investment opportunities overall. At its core, this category targets products that slow or reverse aging, tap into human vanity, and measurably improve health, performance, and happiness. Better sleep improves all of those "biomarkers". Crucially, I believe a significant share of this value will be captured at the distribution layer - specifically by telehealth platforms such as $HIMS, as well as our own “Live Enhanced” platform, a core business line of the @enhanced_games - ticker $APAD soon $ENHA 🚀





Are two pro-longevity interventions in a tug-of-war with each other? A new study suggests that rapamycin interferes with exercise, blunting its effects in older humans. This result, however, might be specific to the particular protocol. lifespan.io/rapamycin-migh… By @ArkadyMazin






